Literature DB >> 9062445

Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection.

D K Owens1, A B Cardinalli, R F Nease.   

Abstract

An understanding of quality of life (QOL) with human immunodeficiency virus (HIV) is important because the merits of prevention and treatment alternatives may depend substantially on how these interventions affect QOL. Physicians' views about QOL are important, because they influence the therapeutic options that physicians consider or offer, the recommendations that physicians make, and because they are important for the analysis of certain policy questions. We assessed physicians' utilities of health states associated with HIV infection, and hepatitis B virus (HBV) infection; assessment of utilities for HBV was induced to provide a comparison with HIV utilities. We surveyed 200 housestaff and staff physicians in an academic medical centre by anonymous paper-based questionnaire and used the time-tradeoff method to assess physicians' utilities of the health states. On a scale in which 0 was equivalent to death, and 1 was equivalent to good health, the median utilities for asymptomatic HIV infection, symptomatic HIV infection, and AIDS were 0.833, 0.417, and 0.167, respectively (p < 0.01 or each two-way comparison). Median utilities for asymptomatic HBV infection, mildly symptomatic HBV infection, and severely symptomatic HBV infection were 0.917, 0.667, and 0.167, respectively (p < 0.01 for each two-way comparison). Although physicians varied substantially in the ratings of health states, they assessed the utility of life with HIV disease, including asymptomatic infection, as severely reduced. Studies of the effectiveness and cost-effectiveness of preventive and therapeutic interventions for HIV should evaluate the effect of the intervention on utility-based assessments of QOL. Studies that do not assess such effects may significantly underestimate or overestimate the value of these interventions, depending on the intervention's effect on QOL.

Entities:  

Mesh:

Year:  1997        PMID: 9062445     DOI: 10.1023/a:1026473613487

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  29 in total

1.  Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex.

Authors:  A W Wu; W C Mathews; L T Brysk; J H Atkinson; I Grant; I Abramson; C J Kennedy; J A McCutchan; S A Spector; D D Richman
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group.

Authors:  R D Gelber; W R Lenderking; D J Cotton; B F Cole; M A Fischl; A Goldhirsch; M A Testa
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

3.  The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

Authors:  D G Fryback; E J Dasbach; R Klein; B E Klein; N Dorn; K Peterson; P A Martin
Journal:  Med Decis Making       Date:  1993 Apr-Jun       Impact factor: 2.583

4.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.

Authors:  B F Gage; A B Cardinalli; G W Albers; D K Owens
Journal:  JAMA       Date:  1995-12-20       Impact factor: 56.272

5.  Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial. Roche 3300/ACTG 114 Study Group.

Authors:  S A Bozzette; D E Kanouse; S Berry; N Duan
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272

6.  Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-12-22       Impact factor: 17.586

7.  Cost-effectiveness of HIV screening in acute care settings.

Authors:  D K Owens; R F Nease; R A Harris
Journal:  Arch Intern Med       Date:  1996-02-26

8.  Fallacy of the five-year survival in lung cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245

9.  The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life.

Authors:  B F Gage; A B Cardinalli; D K Owens
Journal:  Arch Intern Med       Date:  1996-09-09

10.  Assessing the preferences of patients with psoriasis. A quantitative, utility approach.

Authors:  K A Zug; B Littenberg; R D Baughman; T Kneeland; R F Nease; W Sumner; G T O'Connor; R Jones; E Morrison; R Cimis
Journal:  Arch Dermatol       Date:  1995-05
View more
  11 in total

1.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

2.  Adjusting distributions of the Health Utilities Index Mark 3 utility scores of health-related quality of life.

Authors:  Jian Sun
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

3.  The effect of diagnosis with HIV infection on health-related quality of Life.

Authors:  Shyoko Honiden; Vandana Sundaram; Robert F Nease; Mark Holodniy; Laura C Lazzeroni; Andrew Zolopa; Douglas K Owens
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

4.  The cost-effectiveness of screening for chronic hepatitis B infection in the United States.

Authors:  Mark H Eckman; Tiffany E Kaiser; Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2011-05-02       Impact factor: 9.079

5.  Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease.

Authors:  C D Wells; W B Murrill; M R Arguedas
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

6.  Population-based utilities for upper extremity functions in the setting of tetraplegia.

Authors:  Ashwin N Ram; Catherine M Curtin; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2009-11       Impact factor: 2.230

7.  Economic methods for measuring the quality of life associated with HIV infection.

Authors:  A M Bayoumi; D A Redelmeier
Journal:  Qual Life Res       Date:  1999-09       Impact factor: 3.440

8.  Physicians' preference values for hepatitis C health states and antiviral therapy: a survey.

Authors:  R Patil; S J Cotler; G Banaad-Omiotek; R A McNutt; M D Brown; S Cotler; D M Jensen
Journal:  BMC Gastroenterol       Date:  2001-08-01       Impact factor: 3.067

9.  Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionals.

Authors:  Sujin Cho; Hochang Kim; Seon-Ha Kim; Minsu Ock; Yeon-Mok Oh; Min-Woo Jo
Journal:  Health Qual Life Outcomes       Date:  2015-03-13       Impact factor: 3.186

10.  Do medical house officers value the health of veterans differently from the health of non-veterans?

Authors:  Michael S Yi; Sara Luckhaupt; Joseph M Mrus; Joel Tsevat
Journal:  Health Qual Life Outcomes       Date:  2004-04-07       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.